{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=23", "query": { "intervention": "Peptide vaccine", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 749, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:03:57.760Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00085189", "title": "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Metastatic Intraocular Melanoma", "Mucosal Melanoma", "Recurrent Intraocular Melanoma", "Recurrent Melanoma", "Stage IIC Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIA Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIB Melanoma", "Stage IIIC Intraocular Melanoma", "Stage IIIC Melanoma", "Stage IV Intraocular Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "recombinant MAGE-3.1 antigen", "type": "BIOLOGICAL" }, { "name": "multi-epitope melanoma peptide vaccine", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "agatolimod sodium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 42, "start_date": "2004-05", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085189" }, { "nct_id": "NCT02049489", "title": "A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "ICT-121 DC vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precision Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-12", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2018-08-13", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 6, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Edison", "state": "New Jersey" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049489" }, { "nct_id": "NCT00088985", "title": "Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 56, "start_date": "2004-01", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088985" }, { "nct_id": "NCT00613509", "title": "Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Cancer" ], "interventions": [ { "name": "ALVAC(2) Melanoma multi-antigen therapeutic vaccine", "type": "BIOLOGICAL" }, { "name": "Intron A, Interferon alpha -2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2008-06", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 15, "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00613509" }, { "nct_id": "NCT02639234", "title": "Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-small Cell Lung Cancer", "Metastatic Non-small Cell Lung Cancer", "Lung Neoplasms" ], "interventions": [ { "name": "Vigil™", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-03", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-07-31", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 3, "location_summary": "Abilene, Texas • Dallas, Texas • Spokane Valley, Washington", "locations": [ { "city": "Abilene", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Spokane Valley", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639234" }, { "nct_id": "NCT01836432", "title": "Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable", "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "5-FU Chemoradiation", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2013-05", "completion_date": "2017-03-24", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 32, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836432" }, { "nct_id": "NCT00861406", "title": "Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pegylated Interferon-Alfa 2b (PEG Intron)", "type": "DRUG" }, { "name": "GP-100 Peptide Vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2009-03-10", "completion_date": "2017-02-24", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861406" }, { "nct_id": "NCT04580771", "title": "A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Stage IB3 Cervical Cancer FIGO 2018", "Stage II Cervical Cancer FIGO 2018", "Stage IIA Cervical Cancer FIGO 2018", "Stage IIA1 Cervical Cancer FIGO 2018", "Stage IIA2 Cervical Cancer FIGO 2018", "Stage IIB Cervical Cancer FIGO 2018", "Stage III Cervical Cancer FIGO 2018", "Stage IIIA Cervical Cancer FIGO 2018", "Stage IIIB Cervical Cancer FIGO 2018", "Stage IIIC Cervical Cancer FIGO 2018", "Stage IIIC1 Cervical Cancer FIGO 2018", "Stage IIIC2 Cervical Cancer FIGO 2018", "Stage IVA Cervical Cancer FIGO 2018" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2020-10-14", "completion_date": "2027-03-08", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580771" }, { "nct_id": "NCT02737787", "title": "A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube", "Primary Peritoneal Cancer", "Recurrent Ovarian Cancer" ], "interventions": [ { "name": "WT1 Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "NY-ESO-1 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2016-04", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2023-04-07", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02737787" }, { "nct_id": "NCT01339663", "title": "Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "autologous tumor cell vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2012-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-15T13:03:57.760Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01339663" } ] }